Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $7.3 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 20.6% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $28.7 million (down 17.71% YoY), and the FY2025 full-year result was $28.7 million, down 17.71% from the prior year.
• Share-based Compensation for Q4 2025 stood at $7.3 million, up from $4.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.2 million in Q4 2024, with the low at $2.5 million in Q1 2021.
• Historically, Share-based Compensation has averaged $6.1 million across 5 years, with a median of $6.4 million in 2023.
• Annual changes were most pronounced in 2021 — Share-based Compensation jumped 20683.33% — and 2025, when it sank 54.79%.
• Keros Therapeutics' Share-based Compensation stood at $3.3 million in 2021, then surged by 44.04% to $4.7 million in 2022, then surged by 54.32% to $7.3 million in 2023, then grew by 25.61% to $9.2 million in 2024, then dropped by 20.6% to $7.3 million in 2025.
• The last three Share-based Compensation figures came in at $7.3 million (Q4 2025), $4.0 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.